Neuway Pharma GmbH, a Bonn, Germany-based company that focuses on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases, raised €2.7m in Series A financing.
The round was led by Wellington Partners.
Founded in April 2014 as the first spin-off from Life Science Inkubator, Neuway is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary Central Nervous System (CNS) drug delivery platform.
The company also intends to partner its drug delivery technology for other CNS indications.
Shareholders in Neuway include and Dr. Heiko Manninga, Dr. Lucio van Rooijen, who had advised Life Science Inkubator for the last 12 months on the spin-off, as well as Dr. Stephan Rapp, Managing Director at biovenco consulting GmbH.
The project had been incubated within LSI for the last 4 years and supported with approx. € 2.3m in research funding by the Federal Ministry of Education and Research.